Skip to content
Erasca, Inc. logo — Our mission at Erasca is embedded in our name: To erase canc...

Erasca, Inc.

Our mission at Erasca is embedded in our name: To erase cancer.

Founded 2018 United States San Diego, United States 114 employees Post-IPO Equity Total: $629.00M Biotechnology, Life Sciences +1

General Information

Company Name Erasca, Inc.
Founded Year 2018
Location United States San Diego, United States
Employees 114
Industries Biotechnology, Life Sciences, Pharmaceutical
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Erasca, Inc.. To contact Erasca, Inc., visit erasca.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Erasca, Inc. compare?

A PDF of Erasca, Inc. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Erasca, Inc. soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Erasca, Inc.

Erasca, a biotechnology and pharmaceutical company founded in 2018, is on a mission to "erase cancer." The company's commitment to addressing oncology's toughest challenges is fueled by recent scientific breakthroughs and advancements in targeting various biological drivers of cancer. Erasca has strategically built a formidable team and established collaborations with renowned partners who share their ambitious vision. The company's efforts extend beyond their initial programs, as they actively seek to expand their pipeline through partnerships with academic scientists and biopharmaceutical entities to explore potential new mechanisms for precision oncology. Erasca operates with a forward-thinking approach, avoiding constraints on a specific type of drug or treatment method. This flexibility is aimed at maximizing results for cancer patients globally. In March 2024, Erasca secured a significant $45.00M post-IPO equity investment, signaling investor confidence in the company's endeavors. As a United States-based entity, Erasca's dedication to eradicating cancer aligns with the evolving landscape of precision medicine, positioning the company as a notable player in the biopharmaceutical industry.

Business keywords: Oncology, Precision Medicine, Drug Development, Cancer Research, Biopharmaceutical, Precision Oncology, Biology, Collaborations, Pipeline Expansion, Scientific Discoveries, Precision Oncology Options, Academic Partnerships, San Diego, California

Funding Rounds & Investors (7)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $184.00M -
16 May 2024
Post IPO Equity $45.00M -
27 Mar 2024
Post IPO Equity $100.00M -
09 Dec 2022
Series B $36.00M 2
OrbiMed, PFM Health Sciences
31 Aug 2020
Series B $200.00M 8
Arch Venture Partners, EDBI +6
27 Apr 2020
Series A $22.00M 4
Arch Venture Partners, Andreessen Horowitz/ a16z +2
05 Mar 2019
Series A $42.00M 2
City Hill Ventures, Cormorant Asset Management
18 Dec 2018

Erasca, Inc. Alternatives & Competitors

View All Alternatives
Erasca, Inc. vs

Pioneering cellular pharmacology to discover groundbreaking cancer therapies.

Venture round
11-50 employees
Biopharma, Biotechnology
Erasca, Inc. vs

Adastra is committed to transforming cancer care.

Venture round
11-50 employees
Biotechnology, Health Care
Erasca, Inc. vs

Cancer drug development comes of age.

Post-IPO Equity
190 employees
Biopharma, Biotechnology

FAQ About Erasca, Inc.

Our mission at Erasca is embedded in our name: To erase cancer.
Erasca, Inc. was founded in 2018.
Erasca, Inc. is headquartered in San Diego, United States.
Erasca, Inc. operates in Biotechnology, Life Sciences and Pharmaceutical. Its work centres on Oncology, Precision Medicine, Drug Development and Cancer Research.
Erasca, Inc. has approximately 114 employees.
Erasca, Inc. has completed 7 funding rounds, raising a total of $629.00M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to Erasca, Inc. include Odyssey Thera, Adastra Pharmaceuticals, Day One Biopharmaceuticals, Nexo Therapeutics, GenFleet Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Erasca, Inc. and Odyssey Thera are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Erasca, Inc., https://www.bouncewatch.com/company/erasca, updated 9 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout